David Konstandt, MD
Urology · Mooresville, NCNPI 1881670164
Payments from drug & device makers
Across 79 payments — averaging $55.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$2K
- Astellas Pharma US Inc$557
- Dendreon Pharmaceuticals LLC$530
- C. R. Bard, Inc. & Subsidiaries$400
- Boston Scientific$207
- Medtronic$197
- plus $988 from 23 others
Across 1 payment — averaging $710.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$710
What the payments were for
- Consulting fees$2,41555%
- Food & beverage$1,80841%
- Education$1704%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 2 | $1,515 |
| Astellas Pharma US Inc | 20 | $557 |
| Dendreon Pharmaceuticals LLC | 2 | $530 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $400 |
| Boston Scientific | 10 | $207 |
| Medtronic(2 entities) | 5 | $197 |
| Procept Biorobotics Corporation | 1 | $170 |
| Sumitomo Pharma America, Inc. | 4 | $93 |
| Pfizer | 5 | $81 |
| Neotract Inc. | 2 | $73 |
| Amgen | 4 | $65 |
| Blue Earth Diagnostics | 1 | $50 |
| Bayer | 2 | $47 |
| Ferring Pharmaceuticals Inc. | 2 | $46 |
| Valencia Technologies Corporation | 1 | $45 |
| Tolmar, Inc. | 2 | $42 |
| Coloplast | 2 | $35 |
| Calyxo, Inc. | 1 | $31 |
| Urogen Pharma, Inc. | 1 | $30 |
| Zyla Life Sciences, Inc. | 2 | $27 |
| Laborie Medical Technologies Corp. | 1 | $24 |
| Teleflex LLC | 1 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Tolmar Pharmaceuticals, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Olympus America Inc. | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Dentsply IH Inc. | 1 | $12 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$758
- PROVENGE$500
- AquaBeam Robotic System$170
How this compares
$4,393 in reported general payments places this provider in the 60th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 73 | $1,040,075 |
| OrgovyxRelugolix | 228 | $603,353 |
| NubeqaDarolutamide | 12 | $167,068 |
| MyrbetriqMirabegron | 86 | $79,317 |
| GemtesaVibegron | 49 | $42,544 |
| ElmironPentosan Polysulfate Sodium | 15 | $13,950 |
| Tamsulosin Hcl | 390 | $4,714 |
| Silodosin | 29 | $2,517 |
| Finasteride | 195 | $2,314 |
| Solifenacin Succinate | 23 | $2,110 |
| NitrofurantoinNitrofurantoin Macrocrystal | 38 | $1,453 |
| Potassium Citrate ErPotassium Citrate | 20 | $1,360 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 55 | $1,321 |
| Cephalexin | 111 | $1,260 |
| Bicalutamide | 30 | $1,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $557 | $1,119,392159 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $93 | $645,897277 claims |
| BayerNubeqa | $47 | $167,06812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 434 urology providers in North Carolina.
Other urology in Mooresville
- Stewart PolskyMooresville$165K
- Daniel GeorgeDurham$17.6M
- Robert LippittSmithfield$11.4M
- Thomas PolascikDurham$4.7M
- Judd MoulDurham$4.1M
- John WrennGreensboro$2.9M
- Michael KennellyCharlotte$1.4M
- John KasparRaleigh$1.1M
- Scott MacdiarmidGreensboro$882K
- Glenn PremingerDurham$736K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.